Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3209776 | 0.94 | GID4 (0.40) | POLBCNR1CNR2GID4SMN1; SMN2 | |
| SCHEMBL13490601 | 0.82 | POLB (0.42) | POLBGID4SMN1; SMN2CXCR6USP30 | |
| SCHEMBL13490680 | 0.82 | ADORA1 (0.46) | POLBSMN1; SMN2CXCR6 | |
| SCHEMBL13490630 | 0.80 | SMYD3 (0.56) | CNR2GID4SMN1; SMN2USP30 | |
| SCHEMBL13490676 | 0.80 | SMN1; SMN2 (0.53) | CNR1CNR2GID4SMN1; SMN2USP30 | |
| SCHEMBL14192814 | 0.80 | SMN1; SMN2 (0.53) | CNR1CNR2GID4SMN1; SMN2USP30 | |
| SCHEMBL13490654 | 0.79 | SMN1; SMN2 (0.48) | POLBGID4SMN1; SMN2USP30MAPT | |
| Hydrochloric Acid SCHEMBL3224400 | 0.79 | SMYD3 (0.55) | CNR2GID4SMN1; SMN2USP30 | |
| SCHEMBL13490700 | 0.79 | SMN1; SMN2 (0.49) | CNR2GID4SMN1; SMN2USP30MAPT | |
| SCHEMBL13490493 | 0.79 | NPC1 (0.64) | CNR1CNR2GID4SMN1; SMN2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | POLB 3043/4885CNR1 1762/4885CNR2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.